Accurate differential diagnosis of parkinsonism is of paramount therapeutic and prognostic
importance. In addition, with the development of invasive therapies and novel disease …

This review focuses on recent human 18F-FDG PET studies in Parkinson disease. First, an
overview is given of the current analytic approaches to metabolic brain imaging data. Next …

The differential diagnosis of parkinsonian disorders can be challenging, especially early in
the disease course. PET imaging with [18F]-fluorodeoxyglucose (FDG) has been used to …

Objective: Imaging of regional cerebral glucose metabolism with PET and striatal dopamine
D2/D3 receptors (D2R) with SPECT improves the differential diagnosis of parkinsonism. We …

Purpose Dopamine transporter (DAT) imaging can demonstrate presynaptic dopaminergic
neuronal loss in Parkinson's disease (PD). However, differentiating atypical parkinsonism …

Purpose There are no comprehensive guidelines for the use of FDG PET in the following
three clinical scenarios:(1) diagnostic work-up of patients with idiopathic Parkinson's …

Introduction Positron emission tomography (PET) imaging with F-18 fluorodeoxyglucose
(FDG) has been used to identify characteristic patterns of regional glucose metabolism in …

Recently, revised diagnostic criteria for Parkinson's disease (PD) were introduced (Postuma
et al., 2015). Yet, except for well-established dopaminergic imaging, validated imaging …

Purpose Neuroimaging indicators of Parkinson disease have been developed and applied
in clinical practices. Dopaminergic imaging reflects nigrostriatal dopaminergic dysfunction …

Movement disorders with parkinsonian features are common, and in recent years imaging
has assumed a greater role in diagnosis and management. Thus, it is important that …